Horizon Discovery's UMB Cell-Line Deal Latest Example of Its Academic Collaboration Model

The University of Maryland, Baltimore is now participating in Horizon's "Targeting Cancer Consortium," in which the company supplies its gene-engineering platform to academic researchers, who create cellular disease models that Horizon in-licenses and sells to drug makers.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.